The Problem of Cancer Immunotherapy in Perspective
The basic premises underlying cancer immunotherapy are (a) that cancer cells possess cancer-specific transplantation-like antigens, and (b) that their host is capable of mounting an immune response to these antigens that results in the rejection of the cancer cells as a homograft.
KeywordsLeukemia Sarcoma Prostaglandin Indomethacin PGE2
Unable to display preview. Download preview PDF.
- 1.Braun, W. Cyclic AMP changes as a consequence of tumor-normal cell interactions. In Braun, W., Lichtenstein, L., and Parker, C, eds. Cyclic AMP, Cell Growth and the Immune Response, New York, Springer-Verlag, 1974, pp. 349–357.Google Scholar
- 3.Jerne, N. K., Nordin, A. A., and Henry, C. In Amos, B. and Koprowski, H., eds. Cell Bound Antibodies, Philadelphia; Wistar Institute Press, 1963, pp. 109–116.Google Scholar
- 4.Klein, G. Experimental studies in tumor immunology. Fed. Proc, 28:1739, 1969.Google Scholar
- 6.Plescia, O. J. Tumor-specific antigens: Relationship to immunotherapy and etiology of cancer. In Ceglowski, W. and Friedman, H., eds. Virus Tumorigenesis and Immuno-genesis. New York, Academic Press, 1973, pp. 1–30.Google Scholar
- 8.Sykes, J. and Maddox, I., Prostaglandin production by experimental tumors and effects of anti-inflammatory compounds. Nature [New Biol.], 237:59, 1972.Google Scholar